New vascular endothelial growth factor isoforms promise to increase myocardial perfusion without stealing

Mangialardi, Giuseppe; Madeddu, Paolo

doi:10.1136/heartjnl-2016-309845

Cited by 1 publication

(1 citation statement)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…VEGF-A isoform has been well studied in a number of preclinical studies and several clinical trials. However, VEGF-B and VEGF-D isoforms have attracted much attention from scientists in the past few years [59]. In this regard, Nurro and colleagues demonstrated an angiogenic capacity of new members of the VEGF family, VEGF-B186 and VEGF-D∆N∆C, in porcine myocardium [60].…”

Section: Gene Therapy With Growth Factors For Improving Angiogenesismentioning

confidence: 99%

Recent Advances in Gene Therapy for Cardiac Tissue Regeneration

Kim

Zharkinbekov

Sarsenova

et al. 2021

IJMS

View full text Add to dashboard Cite

Cardiovascular diseases (CVDs) are responsible for enormous socio-economic impact and the highest mortality globally. The standard of care for CVDs, which includes medications and surgical interventions, in most cases, can delay but not prevent the progression of disease. Gene therapy has been considered as a potential therapy to improve the outcomes of CVDs as it targets the molecular mechanisms implicated in heart failure. Cardiac reprogramming, therapeutic angiogenesis using growth factors, antioxidant, and anti-apoptotic therapies are the modalities of cardiac gene therapy that have led to promising results in preclinical studies. Despite the benefits observed in animal studies, the attempts to translate them to humans have been inconsistent so far. Low concentration of the gene product at the target site, incomplete understanding of the molecular pathways of the disease, selected gene delivery method, difference between animal models and humans among others are probable causes of the inconsistent results in clinics. In this review, we discuss the most recent applications of the aforementioned gene therapy strategies to improve cardiac tissue regeneration in preclinical and clinical studies as well as the challenges associated with them. In addition, we consider ongoing gene therapy clinical trials focused on cardiac regeneration in CVDs.

show abstract

Section: Gene Therapy With Growth Factors For Improving Angiogenesismentioning

confidence: 99%